Macrogenics Inc (NAS:MGNX)
$ 4.36 0.25 (6.07%) Market Cap: 273.08 Mil Enterprise Value: 107.83 Mil PE Ratio: 0 PB Ratio: 2.57 GF Score: 60/100

MacroGenics Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 05:00PM GMT
Release Date Price: $11.59 (-1.11%)
Gabriel Cruz;JPMorgan;Analyst

Good morning. My name is Gabriel Cruz, and I'm a member of the health care investment banking team here at JPMorgan. Thank you all for joining us today. Today, I have the pleasure of presenting Scott Koenig, CEO of MacroGenics.

Scott Koenig
MacroGenics, Inc. - CEO, President & Director

Thank you very much. So thank you very much for the opportunity to present at JPMorgan. I will be presenting forward-looking statements during the course of this presentation. So please refer to our SEC filings to understand the risks associated with an investment in MacroGenics.

MacroGenics is a leader in the development of antibody therapeutics for the treatment of cancer. We have developed our company through our core platform technology developed in-house. First one is Fc-engineering, where we've incorporated this technology in 2 of our molecules and have demonstrated coordinate activation of the innate and specific immune responses to produce clinical benefit.

Our second core technology is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot